UroGen PharmaFRA:UR8 +1.20%61 Current Ratio is 4.69 as of Mar. 2026, which is 36% below its 10-year median of 7.37. GuruFocus rates FRA:UR8 with a GF Score™ of 61/100 and a GF Value™ of €16.78 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 1,410 Biotechnology companies, UroGen Pharma ranks better than 55.46% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. UroGen Pharma's current ratio for the quarter that ended in Mar. 2026 was 4.69.
UroGen Pharma has a current ratio of 4.69. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for UroGen Pharma's Current Ratio or its related term are showing as below:
FRA:UR8'
s Current Ratio Range Over the Past 10 Years
Min: 3.04 Med: 7.37 Max: 24.16
Current: 4.69
During the past 11 years, UroGen Pharma's highest Current Ratio was 24.16. The lowest was 3.04. And the median was 7.37.
FRA:UR8's Current Ratio is ranked better than 55.46% of 1410
companies
in the Biotechnology industry
Industry Median: 3.89
vs FRA:UR8: 4.69
UroGen Pharma (FRA:UR8) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
UroGen Pharma Current Ratio Related Terms
UroGen Pharma Current Ratio Historical Data
* Premium members only.
The historical data trend for UroGen Pharma's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:UR8 vs SEPN, FTRE, MLTX: Current Ratio Comparison
For the Biotechnology subindustry, UroGen Pharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UroGen Pharma Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UroGen Pharma's Current Ratio distribution charts can be found below:
* The bar in red indicates where UroGen Pharma's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UroGen Pharma (FRA:UR8) has a Current Ratio of 4.69 as of Mar. 2026. This is 36% below median its historical median of 7.37. Over the past decade, UroGen Pharma's Current Ratio has ranged from 3.04 to 24.16. According to the industry distribution chart, UroGen Pharma ranks #628 out of 1410 companies in the Biotechnology industry, placing it in the top 44.5%.
Is UroGen Pharma's Current Ratio too high?
UroGen Pharma's current Current Ratio of 4.69 is 36% below median its 10-year median of 7.37. Over the past 10 years, this metric has ranged from a low of 3.04 to a high of 24.16. The Biotechnology industry median Current Ratio is 3.89. UroGen Pharma's value of 4.69 is 20.6% above this industry median. Based on the distribution chart, UroGen Pharma ranks #628 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, UroGen Pharma has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's Current Ratio compare to SEPN and FTRE?
According to the Biotechnology industry distribution chart, UroGen Pharma ranks #628 out of 1410 companies for Current Ratio. This puts UroGen Pharma in the upper half of its industry. The industry median Current Ratio is 3.89. UroGen Pharma's value of 4.69 is 20.6% above this benchmark. Historically, UroGen Pharma's own Current Ratio has ranged from 3.04 to 24.16 over the past decade. While the company's 10-year median is 7.37 vs. the industry median of 3.89, UroGen Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UroGen Pharma's current Current Ratio of 4.69 is 20.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UroGen Pharma's current Current Ratio is 4.69, which is 36% below median its own 10-year median of 7.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (FRA:UR8) is currently considered Significantly Overvalued. The stock's GF Value™ is €16.78, compared to a current price of €32.95 — trading 96.4% above its estimated fair value. The current Current Ratio is 4.69, which is 36% below median its 10-year median of 7.37 and 20.6% above the Biotechnology industry median of 3.89. UroGen Pharma's overall GF Score™ is 61/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For UroGen Pharma (FRA:UR8), the current Current Ratio is 4.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UroGen Pharma (FRA:UR8) Overvalued in 2026?
Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued.
The current stock price of €32.95 is trading 96.4% above its estimated GF Value™ of €16.78.
GuruFocus considers UroGen Pharma to be Significantly Overvalued.
Key valuation signals for FRA:UR8:
Current Ratio: 4.69 (36% below median its 10-year median of 7.37)
GF Value™: €16.78 vs. price of €32.95 (96.4% above fair value)
Industry Position: 20.6% above the Biotechnology median (#628 of 1410)
No single metric tells the full story. See the FRA:UR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
61GF Score
Get the complete analysis for FRA:UR8
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UR8 has been successfully added to your 
